Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study
Maiju Savolainen, Merja Soilu‐Hänninen, Henriikka Nurmi, Matias Viitala, Pentti Tienari, Sari Atula, Sini M Laakso · 2026
Read Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study by Maiju Savolainen, Merja Soilu‐Hänninen, Henriikka Nurmi, Matias Viitala, Pentti Tienari, Sari Atula, Sini M Laakso (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13179513.txt.
Description
Maiju Savolainen and co-authors compare two B-cell drugs for relapsing multiple sclerosis in a 2026 Finnish study. Rituximab is used off label, while ocrelizumab holds approval. Registry data from two university hospitals cover 2018 to 2024. After matching, fifty-six patients per drug remain, followed for about three years. Relapse rates, MRI activity, disability, side effects, and antibody levels are tracked.
Relapses stay equally rare on both drugs, they find. MRI scans and disability paths look alike as well. Side effects are few and mild. Antibody levels dip modestly in both groups without more infections. Patients switching drugs show no disease flare in the record.
Catalog record
| CREATOR | Maiju Savolainen, Merja Soilu‐Hänninen, Henriikka Nurmi, Matias Viitala, Pentti Tienari, Sari Atula, Sini M Laakso |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |